Archive for the ‘wrong reagents’ Category
Readers likely know by now how easy it is for this to happen, as we frequently report on retractions due to similar reasons. Like other instances of mistaken cell identity, the authors of this 2013 paper realized the mistake following further tests of the bacteria used in the experiment.
If you could help reduce the waste of tens of billions of dollars per year in research spending, you’d do it, right?
This is the second in a series of two guest posts about the havoc misidentified cell lines can wreak on research, from Leonard P. Freedman, president of the Global Biological Standards Institute. Freedman who published a paper last summer detailing the financial costs of non-reproducible research — namely, tens of billions of dollars per year. Some of that non-reproducible research is due to the use of contaminated or misidentified cell lines. He writes about one key step to tackling the problem: Ask every scientist to use a relatively inexpensive technique to validate the identity of their cell lines.
Meanwhile, we have to deal with the issue of all the previously published papers that relied on problematic cell lines, now contaminating the scientific literature. Scroll down to the bottom of the post to take a poll on what you think should be done about those papers.
As new frontiers of science emerge, from Pluto to proteins, the very cornerstone of the scientific process—reproducibility—has also reared its head as a huge problem. Estimates of irreproducibility rates of published peer-reviewed papers range from 51% to 89%. An analysis that two colleagues and I recently published in PLOS Biology suggests the U.S. spends $28 billion per year on non-reproducible preclinical research; global spending could be up to $60 billion per year. This lack of reproducibility typically results from cumulative errors or flaws in one or more of the following areas: biological reagents and reference materials, study design, laboratory protocols, and data analysis and reporting. Given the size, scale, and especially the complexity of reproducing preclinical research, there is no single magic bullet fix. This is a difficult issue for scientists to own up to, and for the public to grasp.
However, an approach that has demonstrably addressed similar challenges in other complex and evolving industries, such as those involved in the founding of the Internet, is the expanded use of community-based voluntary standards and best practices. And here’s where we start: Read the rest of this entry »
What if we told you that approximately 1 in 6 researchers working with human cells are using the wrong cell line? In other words, they believe they are studying the effects of a drug on breast cancer cells, for instance, but what they really have are cells from the bladder. That is the unfortunate reality in life science research today, affecting hundreds of labs. It’s a major source of problematic papers which cannot be replicated, wasting scientists’ time and funding.
We’re pleased to present a guest post from Amanda Capes-Davis, chair of the International Cell Line Authentication Committee (ICLAC), a voluntary scientific committee created to improve awareness of misidentified cell lines. She also collects news about cell line and culture contamination. This is the first in a series of two posts from guest authors about how problematic cell lines are contaminating the scientific literature, and how we can clean it up.
In 2010, I worked alongside Ian Freshney of Glasgow University and other colleagues to publish a list of cross-contaminated or otherwise misidentified cell lines in the International Journal of Cancer. This database of false cell lines is now curated by the International Cell Line Authentication Committee (ICLAC).
All of us who have contributed to the database are aware that cross-contamination is an important ongoing problem. But I think the number of cell lines affected was a surprise, even to many of us in the field who see these problems on a daily basis. Read the rest of this entry »
Authors have retracted a highly cited Nature letter that purported to discover a much sought-after, stable light source from quantum dots, after they realized the light was actually coming from another source: the glass the dots were affixed to.
When the paper “Non-blinking semiconductor nanocrystals” was published in 2009, it received some media coverage, such as in Chemistry World. That’s partly because very small sources of “non-blinking” light could have wide-ranging, big-picture applications, author Todd Krauss, a physical chemist at the University of Rochester, told us:
Off the top of my head, a quantum computer. Quantum cryptography is another one. People want a stable light source that obeys quantum physics, instead of classic physics.
The retraction note, published Wednesday, explains how the researchers found out the effect was coming from the glass, not quantum dots:
The reasons for the retractions range from expired kits, an “unattributed overlap” with another paper, “authorship issues,” and issues over sample sizes.
Tomader Taha Abdel Rahman, a researcher at Ain Shams University in Cairo, is the first author on two of the papers, and second author on the third.
Here’s the retraction note for a paper that showed elderly adults with chronic hepatitis C are at risk of having cognitive issues:
The author of an article mapping the genome of an infectious bacterium is pulling the paper because — well, it wasn’t the bacterium she thought it was.
Study author Celia Abolnik is retracting her paper in Genome Announcements because it didn’t actually map out the DNA of Mycoplasma meleagridis, a bacterium that typically infects turkeys but has recently been found in chickens.
The trouble was, the sequence for Mycoplasma meleagridis in the National Institute of Health’s DNA database, Genbank, was actually a different variety of bacteria — Mycoplasma gallinaceum, another scourge of poultry.
Researchers at the National Institute of Environmental Health Sciences have retracted a 2014 article after a review unearthed unresolved problems with the study’s control material.
The retracted paper, “Effect of Temperature and Storage Time on Sorbitol Dehydrogenase Activity in Sprague-Dawley Rat Serum and Plasma,” looked to test the durability and stability of sorbitol dehydrogenase, an enzyme used to detect cancerous liver damage in rats.
Upon realizing they had experienced a case of mistaken cell-line identity, the authors of a 2014 Nature paper on lung cancer think “it prudent to retract pending more thorough investigation,” as they explain in a notice published Wednesday.
The problem seems to stem from more than just honest error, according to corresponding author Julian Downward, a scientist at the Francis Crick Institute in the UK.
In a 1,215 word statement, sent to us via the Director of Research Communications and Engagement at Cancer Research UK, which funds Downward’s research, Downward told us the backstory not presented in the journal’s retraction note:
As every mushroom lover knows, weekend mycology is no sport for the lily-livered. Tasty species often look awfully like their deadly cousins. Turns out, typing can even be problematic for the experts.
The paper, “Chemical constituents: water-soluble vitamins, free amino acids and sugar profile from Ganoderma adspersum,” was written by Ibrahim Kivrak, a food chemist at Mugla Sitki Kocman University in Mugla, Turkey. It analyzed the nutritional components of G. adspersum, and found, per the abstract:
Although they are confident that the strategy is sound, the authors write in their commendably detailed retraction notice that the “inadvertent error” rendered the results “uninterpretable.”